Come for the memes, stay to learn and Investment Takes. 100+ Free articles, never charged one cent. NFA. Commentary. 🇺🇸🇺🇸🇺🇸
Join 1000+ for Free Newsletter
Joined April 2021
- Tweets17.1K
- Following244
- Followers12.3K
- Likes123K
Pinned Tweet
I literally don't even understand Incels, just find an overweight but beautiful face girl and inject her with Chinese peptides for 6 months you’ve got an 8/10
I'm saving time and money:
I deleted Facebook, TikTok, Instagram, Netflix, Chatgpt, Claude...
I have everything I need on X and Grok.
$MRNA
Top 10 Lessons for the next Biotech Short Squeeze
1. For market cap perception matters more than anything - retail will pile in beyond any reasonable MC
2. There's a 2 day lag for technical traders (how I made money, but if I had been slower would have melted my face off)
3. If companies don't release the data, there's a reason (see post below, knew it but should have played Esmo)
4. Momentum comes in waves - tech traders set traps
5. I really need to learn more about options strategies. A long straddle with this much volatility likely killed.
6. Journalists will push any sentiment to the extreme - cure for cancer and no data had been released
7. Be wary of any new index adds (predicted but remember)
8. If household name the effect is sustained longer. If this was a no name midcap vs Moderna likely see shorter push.
9. The size of the float is so small given ETFs and long term holdings etc that biotech is beyond reason for squeezes. This was my biggest regret on this play. I instantly recognized it was insane but I underestimated the ability of tech traders in regards to float Size X Manipulation. Add in retail and you can have companies with limited or small Rev gains get Fortune 500 numbers.
10. Technical Traders love Mondays (still not sure why)
I literally posted $MRNA should go up
But $53BN is a bit much isn’t it?
Especially for adjuvant melanoma like sub 25,000 US patients…
When they split revenue 50% with $MRK
Like the biggest move by a S&P500 company ever in one day by a wide margin
Also they didn’t “cure cancer” that’s PR
The hyperbole is the issue, which led to exhuberance, which played a factor in its short squeeze
It’s great for patients to have, but NO data has been released yet Journos and Doctors are glazing.
Can a Doctor get a Kaplan Meier curve? Maybe a Hazard Ratio? Just a peek at a Confidence Interval? Maybe wait to see if any OS benefit?
I hope it works in other tumors but until it does, let’s face it, melanoma is hot. It was the easiest bar to cross.
The company is also not well run. Hence why I shorted it and made bank last month.
Do you think it’s okay for two companies to coordinate a PR push with every major outlet, not provide data, and then not be questioned?
😏😏😏
$MRNA
Tech traders setting traps out here
It's like they learned from $GME and trying to draw retail in
Watch Volume, Order Size, Rate
Some big players
Their biggest weakness is their greed so watch puts....
Part of me really wants to short this again
But the criteria I use tells me it *may* still pump next week so I haven't
Probably the craziest thing I've ever seen in Biotech/Pharma
Still insanely overvalued, are tech traders loosening their grip?
$MRNA
Also AI has made some stuff insanely easy
Write 30-40 letters to the editor of your local newspaper pressuring your Congress over an issue that you care about
Frame it in the worst light
Their staffers/interns read the paper every morning it's basically a pulse on Boomers
If you really care about something
You need to
1. Find out who the power players are
2. Do stuff for them/get favors
3. Make your return favor socially acceptable or provide cover
Pharma is bracing for tougher Treasury scrutiny of China deals, with draft outbound investment rules expected Thursday.
endpoints.news/treasury-expe…
